Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2019
Price :
$35
*
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Novartis
- 04 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2014 New trial record